ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VMD vs CCEL // EV/EBITDA & P/E VALUATION

Viemed Healthcare Inc. (NASDAQ) VS. Cryo-Cell International Inc. (NYSE) • 15-METRIC TALLY: VMD 3 — CCEL 4
▲ EV/EBITDA & P/E VALUATION LEADER: VMD
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VMD VS. CCEL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VMD CCEL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 57.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 13.00% 18.20% -5.20 CCEL /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 6.6x 61.2x -54.60 VMD /valuation <GO>
Free Cash Flow Yield 3.15% 12.55% -9.40 CCEL /fcf-yield <GO>
Operating Margin 8.50% — — TIE /operating-margins <GO>
Net Profit Margin 5.70% — — TIE /net-margins <GO>
Revenue Growth (YoY) 20.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 7.73% -7.73 CCEL /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.59 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 9/9 3/9 +6.00 VMD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.1 64.3 -11.17 CCEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 20.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $379.0M $41.8M $337.2M VMD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VMD REV CCEL REV VMD GROSS % CCEL GROSS % VMD FCF CCEL FCF
FY 2025 $270.3M $0 57.5% — $11.9M $5.2M
FY 2024 $224.3M $0 59.4% — $1.3M $3.6M
FY 2023 $183.0M $0 — — $45.2M $8.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VMD // BETA —
CCEL // BETA —